Fig. 6

PLC–PKC inhibition prevents myosin II apical recruitment independently of myosin phosphorylation. a GFP-MRLC or GFP-MRLC-DD overexpressing embryos were injected with Ruby or PLC-DN and fixed at the late 8-cell stage. b Percentage of blastomeres showing a polarised GFP-MRLC or GFP-MRLC-DD in the groups of (a). N = 17 embryos for Ruby + MRLC, N = 17 embryos for PLC-DN + MRLC and N = 17 embryos for PLC-DN + MRLC-DD, three independent experiments. c Scheme of PLC–PKC inhibitor treatment experiments. d GFP-MRLC or GFP-MRLC-DD overexpressing embryos were treated with DMSO or U73122 and fixed at the late 8-cell stage. e Percentage of blastomeres showing a polarised GFP-MRLC or GFP-MRLC-DD in the groups of (d). N = 11 embryos for DMSO + MRLC, N = 11 embryos for U73122 + MRLC and N = 9 embryos for U73122 + MRLC-DD, four independent experiments. f GFP-MRLC or GFP-MRLC-DD overexpressing embryos were treated with DMSO or sphingosine and fixed at the late 8-cell stage. g Percentage of blastomeres showing a polarised GFP-MRLC or GFP-MRLC-DD in the groups of (f). N = 20 embryos for DMSO + MRLC, N = 9 embryos for sphingosine + MRLC and N = 20 embryos for sphingosine + MRLC-DD, two independent experiments. h GFP-MRLC or GFP-MRLC-DD overexpressing embryos were treated with DMSO or ML-7 and fixed at the late 8-cell stage. i Percentage of polarised blastomeres in the groups of (h). N = 18 embryos for DMSO + MRLC, N = 17 embryos for ML-7 + MRLC, N = 15 embryos for DMSO + MRLC-DD, N = 18 embryos for ML-7 + MRLC-DD, two independent experiments. For all, the quantifications data are shown as a contingency table and the n number in each bar indicates the total number of blastomeres analysed. Squares indicate the magnified regions. ****p < 0.0001, NS = not significantly different, Fisher’s exact test. All scale bars, 15 µm